UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Act of 1934

 

Date of Report (Date of earliest event reported): November 8, 2018

 

NEOS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction of
incorporation or organization)

 

001-37508
(Commission
File Number)

 

27-0395455
(I.R.S. Employer
Identification Number)

 

2940 N. Highway 360
Grand Prairie, TX 75050
(972) 408-1300
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

Item 8.01.                                        Other Events.

 

On November 8, 2018, Neos Therapeutics, Inc. (the “Company”) closed its previously-announced underwritten public offering (the “Offering”) of 19,999,999 shares of common stock at a public offering price of $2.30 per share (inclusive of 2,608,695 shares pursuant to the exercise in full of the underwriters’ option to purchase additional shares). Pursuant to Second Amendment to Facility Agreement (the “Amendment”), dated as of November 5, 2018, among the Company and Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P., the Amendment has become effective upon the closing of the Offering.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

NEOS THERAPEUTICS, INC.

 

 

 

 

Date:

November 8, 2018

 

By:

/s/ Gerald McLaughlin

 

Title:

President and Chief Executive Officer

 

2